Logo

AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-IIIb DIALIZE Study to Treat Hyperkalaemia in Patients with End-Stage Renal Disease

Share this

AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-IIIb DIALIZE Study to Treat Hyperkalaemia in Patients with End-Stage Renal Disease

Shots:

  • The P-IIIb DIALIZE study results involve assessing of Lokelma vs PBO in n 196 patients on hemodialysis with hyperkalemia in ESRD
  • The P-IIIb DIALIZE study resulted in maintaining normal potassium level (4-5 mmol/L) in 41.2% patients receiving Lokelma vs 1% receiving PBO- presented at ERA-EDTA
  • Lokelma is an oral- formulated as suspension and commercially available in the US & EU for the treatment of hyperkalemia in adults

Ref: AstraZeneca | Image: AstraZeneca

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions